Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heart Failure With Reduced Ejection Fraction Polypill in Sri Lanka
NCT07569640Phase 3Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin + atorvastatin + hydrochlorothiazide + enalapril in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations. Started Aug 2026; status: recruiting.
02
Drugs
aspirin + atorvastatin + hydrochlorothiazide + enalapril
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07569640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569640.